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http://djournal homepage: www.elsevier.com/locate/lrrEditorialLeukemia Research Reports: Guide for authorsLeukemia Research Reports is an open access, international
journal which delivers timely information online to all health care
professionals involved in basic and/or applied clinical research in
leukemias, lymphomas, multiple myeloma and other hematologic
malignancies. It does this by rapidly publishing a range of peer-
reviewed short form papers, including brief communications, case
reports, letters to the Editors, images, and debate articles. The
Editors encourage the submission of articles relevant to normal
and leukemic hemopoiesis, biochemistry, cell biology, immunology
andmolecular biology as well as epidemiologic and clinical studies.
Leukemia Research Reports’ coverage encompasses the application
of oncogenes, genomics (gene expression proﬁles and microRNAs),
proteomics, growth factors, cell markers, cell cycle and differentia-
tion agents, novel therapeutics and clinical trials in both the acute
and chronic leukemias as well as the myelodysplastic syndromes.
In addition articles are solicited on the rapidly growing specialty of
marrow or stem cell reconstitution after high dose therapy with
curative attempt in patients with a wide range of neoplasms.
Publishing policy—All articles will be peer reviewed and if
accepted for publication in the Journal, Authors will be notiﬁed of
this decision and at the same time requested to pay an Article
Processing Fee of US$ 600/EUR 458/JPY 46,638 (exclusive of VAT/
Sales Tax). Following payment of this fee, articles will be made
universally available at no further charge through ScienceDirect
and through the Journal’s own website www.lrreports.com.
Submission of Manuscripts – All Manuscripts and Material
should be submitted on-line via EES-http://ees.elsevier.com/lrr/
Please refer to the ‘Tutorial for Authors’ located on the EES site
for guidance on the electronic submission process.
All published papers containing research data are subject to
peer-review. Submission of an article implies that the work
described has not been published previously and will not be
simultaneously submitted or published elsewhere (except in the
form of an abstract or as part of a published lecture or academic
thesis), that it is not under consideration for publication else-
where, that its publication is approved by all authors and tacitly
or explicitly by the responsible authorities where the work was
carried out, and that, if accepted, it will not be published else-
where in the same form, in English or in any other language,
without the written consent of the Publisher.
These guidelines generally follow the ‘Uniform Requirements
for Manuscripts Submitted to Biomedical Journals’. The complete
document appears at-http://www.icmje.org.
Submitting an Article—Articles should be submitted online at
-http://ees.elsevier.com/lrr/ and the instructions on the site
should be closely followed. Authors may submit manuscripts
and track their progress to ﬁnal decision.89 & 2012 Published by Elsevier Ltd.
x.doi.org/10.1016/j.lrr.2012.11.002
Open access under CC BY-NC-ND license.Types of Contribution—All articles are limited by word count
and the number of references. Word count limits do not include
the abstract, references, acknowledgment, ﬁgures or tables, or
their captions.
Brief Communications include an abstract; the total word
count should not exceed 1200 words, a maximum of 10 refer-
ences and up to 4 ﬁgures and/or tables.
Case Reports include an abstract; they should not exceed 1200
words, a maximum of 10 references and an optional 1–2 ﬁgures
and/or tables.
Letters to the Editor should clearly indicate the purpose of the
letter by a brief striking title; they should include an abstract and
should not exceed 1200 words, up to 5 references and an optional
1–2 ﬁgures and/or tables.
Debate and Controversies—the journal welcomes opinion
pieces on research and clinical topics in leukemia. Debate &
Controversies articles should include an abstract, should not
exceed 1200 words, plus a maximum of 5 references and 1 ﬁgure
or table.
Images—authors are encouraged to submit images for pub-
lication. These should be accompanied by a title and a caption
that explains the signiﬁcance of the image. In addition to ‘still life
‘ images, authors may submit video ﬁles. For full details of
artwork formats see below.
Meeting Perspectives are reports on one or several sessions of
Congress, Workshops or Symposia (also closed ones). Such papers
should not exceed 1200 words, 5 references and up to 2 ﬁgures
and/or tables.
Comments on Published Papers are comments on a prior
published paper. Mention the title in both the Cover Letter and
the References. This paper does not have an abstract and should
not exceed 1200 words; limit 3 references and optional 1–2
ﬁgures and/or tables. Comments that seek to address an error in
a previous paper are exempt from the Article Processing Fee if
accepted for publication.
Preparation of Manuscripts
1. Covering letter: This is a letter stating that you wish to
submit your paper to Leukemia Research Reports. Please include
the title, and signature of corresponding author. Also include
details of any previous version.
2. All contributions must be 1.5 spaced except the references
which are single spaced with a space between each reference.
3. Manuscripts submitted for publication should be written
concisely and clearly. Manuscripts will only be accepted when
they are written in an acceptable standard of English (American
or British usage is accepted, but not a mixture of these). Authors
whose native language is not English are strongly advised to have
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prior to submission or to submit them for language editing (see
below for more details). Either the Concise Oxford Dictionary or
Webster’s New International Dictionary may be used as a stan-
dard for English spelling.
4. The manuscript should be organized in the following
sequence: All manuscripts must have a title page which is Page
1 of your manuscript. Note the Title should be clear, descriptive
and less than 20 words long. Avoid non-speciﬁc phrases such as ‘A
study ofy’ or ‘The effects ofy’. Do not give the title a numbered
subtitle or series number.
The title page is the ﬁrst page of the paper and must contain
the following: title name of authors (listed as, ﬁrst name last
name academic degree then superscript the institutional code);
institutional has superscript code (1, 2, 3,y), Department ofy,
institution, city and country; the Corresponding Author. Note: No
positions like Dr., Professor, or Faculty of, we use academic
degrees only.
Role of Corresponding Author: Please note there is only one
corresponding author of the manuscript. The corresponding
author is the one that submits the manuscript and is displayed
on the Title Page of the manuscript. They have the duty to ensure
that all of the named authors have seen and approved the original
manuscript and subsequent revisions. Each author should have
participated sufﬁciently in the work to take public responsibility
for the content. The corresponding author should also ensure that
those who have contributed to the research are acknowledged
appropriately either as a co-author or in the Acknowledgments. In
addition, the corresponding author has the prime responsibility
for ensuring the paper is correctly prepared according to the
Guide for Authors. Submitted manuscripts not complying with
the Guide for Authors may be returned to the authors for revision.
Word Count: does not include the references, acknowledgment,
ﬁgures and tables.
Abstract: The abstract should be clear, descriptive and less than
100 words.
Keywords—Keywords are index terms or descriptions for
information retrieval systems, and a maximum of ﬁve should be
provided. Words selected should reﬂect the essential topics of the
article and may be taken from both the title and the text.
Abbreviations and units: Generally, avoid abbreviations in the
Title and abbreviating single words. Otherwise explain all abbre-
viations at ﬁrst mention in the abstract and text, except for: DNA,
RNA, AIDS, and HIV. Standard SI abbreviations for units do not
need to be spelled out.
Brief Communications should include an Introduction, Materi-
als and Methods, Results and Discussion sections. Case Reports
and Letters to the Editor do not need to include these divisions.
Introduction: This should give the reasons for doing the work.
As this is a specialist journal a detailed review of the literature is
not necessary. The introduction should preferably conclude with a
ﬁnal paragraph stating concisely and clearly the aims and objec-
tives of the investigation.
Materials and Methods: A full technical description of a method
should be given in detail only when the method is new.
Results: This need only report results of representative experi-
ments illustrated by tables and ﬁgures. Use well-known statistical
tests in preference to obscure ones. Consult a statistician or a
statistics text for detailed advice.
Discussion (including Conclusions): This section must not reca-
pitulate results but should relate the authors’ experiments to
other work and give their conclusions, which may be given in a
subsection headed after called Conclusions.
References: References are numbered. All publications cited in
the text should be presented in a list of references following the
text of the manuscript. In the text refer to references by a numberin square brackets on the line (e.g. Since Peterson [1]), and the full
reference should be given in a numerical list at the end of the
paper. References should be given in the following form: 1.
Latagliata R, Concetta Petti M, Mandelli F. Acute myeloid leukemia
in the elderly: ‘per aspera ad astra’? Leukemia Res 1999;23:603–
613. 2. Alfrey V. The isolation of subcellular components. In:
Brachet J, Mirsky AE, editors. The cell, biochemistry, physiology,
morphology I. New York: Academic Press, 1959. p. 200.
Note: Authors are strongly encouraged to check the accuracy of
each reference against its original source. Work accepted for
publication but not yet published should be referred to as ‘in
press’. Authors should provide evidence (such as a copy of the
letter of acceptance). References concerning unpublished data,
theses, and ‘personal communications’ should not be cited in the
reference list but may be mentioned in the text. Do not only put
the ﬁrst author et al. list all authors.
5. Acknowledgments should be organized in the following
sequence.
Acknowledgments—All contributors who do not meet the
criteria for authorship as deﬁned above should be listed in an
acknowledgments section. E.g. those who might be acknowledged
include a person who provided purely technical help, writing
assistance, or a department chair that provided only general
support. Authors should disclose whether they had any writing
assistance and identify the entity that paid for this assistance.
Role of the funding source—All sources of funding should be
declared. Authors should declare the role of study sponsors, if any,
in the study design, collection, analysis and interpretation of data;
in the writing of the manuscript; and in the decision to submit the
manuscript for publication. If the study sponsors had no such
involvement, the authors should so state.
Authors’ Contributions—All authors should have made sub-
stantial contributions to the following: (1) the conception and
design of the study, or acquisition of data, or analysis and
interpretation of data. (2) drafting the article or revising it
critically for important intellectual content. (3) ﬁnal approval of
the version to be submitted. For authors we use initials and if
there is more than one author that does the same function put
them together. Note: If there is more than one author that
contributed equally to the work it goes in this section not on
the title page.
Conﬂict of Interest—All authors must disclose any ﬁnancial
and personal relationships with other people or organizations
that could inappropriately inﬂuence (bias) their work. E.g. poten-
tial conﬂicts of interest include employment, consultancies, stock
ownership, honoraria, paid expert testimony, patent applications/
registrations, and grants or other funding. If there no conﬂicts of
interest exist this must be stated. Please see the Elsevier website
for further information http://www.elsevier.com/wps/ﬁnd/
authorsview.authors/conﬂictsoﬁnterest.
6. Figures and Figure Legends—Figures should be cited
consecutively in the text. Full details for the electronic submission
of artwork can be obtained from http://www.elsevier.com/artwor
kinstructions. All ﬁgures have to be uploaded in EES separately.
For further information on the preparation of electronic art-
work, please see http://www.elsevier.com/artworkinstructions.
Type the ﬁgure legends in order in one word document and
starting with the words ﬁgure legends; limit 40 words or less.
Spacing is 1.5 and if more than one page put a page number in the
footer.
7. Table and Table Legends—Tables should be cited consecu-
tively in the text. Type tables on separate pages with a title. Avoid
white spaces in the table by using footnotes, and ensure all
symbols or abbreviation are explained. Take care to distinguish
between ‘zero’ and ‘not done’ as an entry in the table. Tables are
uploaded separately.
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starting with the words table legends. Spacing is 1.5 and if more
than one page put a page number in the footer.
Footnotes: Footnotes should only be used to provide addresses
of authors or to provide explanations essential to the under-
standing of Tables.
8. Supplementary Data—As Leukemia Research Reports focuses
on short papers, Supplementary Data ﬁles are not accepted.
Ethics—Identifying information, including patients images,
names, initials, or hospital numbers, should not be included in
videos, recordings, written descriptions, photographs, and pedi-
grees unless the information is essential for scientiﬁc purposes
and you have obtained written informed consent for publication in
print and electronic form from the patient (or parent, guardian or
next of kin where applicable). If such consent is made subject to
any conditions, Elsevier must be made aware of all such condi-
tions. Written consents must be provided to Elsevier on request.
Even where consent has been given, identifying details should
be omitted if they are not essential. If identifying characteristics
are altered to protect anonymity, such as in genetic pedigrees,
authors should provide assurance that alterations do not distort
scientiﬁc meaning and editors should so note.
If such consent has not been obtained, personal details of
patients included in any part of the paper and in any supplemen-
tary materials (including all illustrations and videos) must be
removed before submission.
Drug names—Use generic names for drugs. Commercial
names may be included in parentheses at ﬁrst mention in the
text. Complicated drug names or regimens may be abbreviated,
with the abbreviation in parentheses after ﬁrst mention.
Revised Manuscript—All manuscripts are peer-reviewed. On
receipt of the ﬁrst decision letter authors should send their
revised manuscript as soon as possible in order to ensure that
the scientiﬁc content of their manuscript is timely and up to date.
The revised paper must be submitted without tracking or
highlights and 1.5 spaced. A Revision Letter must contain detailed
responses to the reviewers and indicate where in the letter you
changed the text.
Author Names—This policy concerns the addition, deletion, or
rearrangement of author names in the authorship of accepted
manuscripts: Before the accepted manuscript is published in an
online issue: Requests to add or remove an author, or to rearrange
the author names, must be sent to the Journal Manager from the
corresponding author of the accepted manuscript and must
include the following: (a) the reason the name should be added
or removed, or the author names rearranged and (b) written
conﬁrmation (e-mail, fax, and letter) from all authors that they
agree with the addition, removal or rearrangement. In the case of
addition or removal of authors, this includes conﬁrmation from
the author being added or removed. Requests that are not sent by
the corresponding author will be forwarded by the Journal
Manager to the corresponding author, who must follow the
procedure as described above. Note that (1) Journal Managers
will inform the Journal Editors of any such requests and (2) pub-
lication of the accepted manuscript in an online issue is sus-
pended until authorship has been agreed. After the accepted
manuscript is published in an online issue: Any requests to add,
delete, or rearrange author names in an article published in an
online issue will follow the same policies as noted above and
result in a corrigendum.
Copyright—Upon acceptance of an article, authors will be
asked to sign a Journal Publishing Agreement. This includes
details of the rights that you retain as author (for more informa-
tion on this and copyright see http://www.elsevier.com/wps/ﬁnd/
authorsview.authors/authorsrights). An e-mail will be sent to the
corresponding author conﬁrming receipt of the manuscripttogether with a Journal Publishing Agreement form. Following
signature of this form and payment of the Author Fee, case reports
will be made universally accessible through -ScienceDirect and
through the Journal’s own website, www.lrreports.com.
If excerpts from other copyrighted works are included, the
author(s) must obtain written permission from the copyright
owners and credit the source(s) in the article. Elsevier has
preprinted forms for use by authors in these cases; contact
Elsevier s Rights Department, Philadelphia, PA, USA: Tel. (þ1)
215 238 7869; Fax (þ1) 215 238 2239; e-mail healthpermission-
s@elsevier.com. Requests may also be completed online via the
Elsevier homepage (http://www.elsevier.com/locate/permissions).
Proofs—One set of page proofs in PDF format will be sent by e-
mail to the corresponding author. Elsevier now sends PDF proofs
which can be annotated; for this you will need to download
Adobe Reader version 7 available free from-http://www.adobe.
com/products/acrobat/readstep2.html. Instructions on how to
annotate PDF ﬁles will accompany the proofs. The exact system
requirements are given at the Adobe site: -http://www.adobe.
com/products/acrobat/acrrsystemreqs.html#70win. If you do not
wish to use the PDF annotations function, you may list the
corrections (including replies to the Query Form) and return to
Elsevier in an e-mail. Please list your corrections quoting line
number. If, for any reason, this is not possible, then mark the
corrections and any other comments (including replies to the
Query Form) on a printout of your proof and return by fax, or scan
the pages and e-mail, or by post.
Please use this proof only for checking the typesetting, editing,
completeness and correctness of the text, tables and ﬁgures.
Signiﬁcant changes to the article as accepted for publication will
only be considered at this stage with permission from the Editor.
We will do everything possible to get your article published
quickly and accurately. Therefore, it is important to ensure that all
of your corrections are sent back to us in one communication:
please check carefully before replying, as inclusion of any sub-
sequent corrections cannot be guaranteed. Proofreading is solely
your responsibility. Note that Elsevier may proceed with the
publication of your article if no response is received.
Language services—Authors who require information about
language editing and copyediting services pre- and post-
submission should visit -http://webshop.elsevier.com/language
services or our customer support site at-http://support.elsevier.
com for more information.
Enquiries—Authors can keep a track on the progress of their
accepted article, and set up e-mail alerts informing them of
changes to their manuscript’s status, by using the ‘Track a Paper’
feature at: http://www.elsevier.com/trackarticle. For privacy,
information on each article is password-protected. The author
should key in the ‘Our Reference’ code (which is in the letter of
acknowledgment sent by the publisher on receipt of the accepted
article) and the name of the corresponding author. In case of
problems or questions, authors may contact the Author Service
Department, E-mail: authorsupport@elsevier.com
Offprints—The corresponding author, at no cost, will be
provided with a PDF ﬁle of the article via e-mail. The PDF ﬁle is
a watermarked version of the published article and includes a
cover sheet with the journal cover image and a disclaimer
outlining the terms and conditions of use.
& 2012 Elsevier Ltd. All rights reserved—This journal and the
individual contributions contained in it are protected under
copyright by Elsevier Ltd. Please click on User Rights for a
summary of how articles published in Leukemia Research Reports
can be utilized.
Notice—No responsibility is assumed by the Publisher for any
injury and/or damage to persons or property as a matter of
products liability, negligence or otherwise, or from any use or
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contained in the material herein. Because of rapid advances in
the medical sciences, in particular, independent veriﬁcation of
diagnoses and drug dosages should be made. Although all
advertising material is expected to conform to ethical (medical)standards, inclusion in this publication does not constitute a
guarantee or endorsement of the quality or value of such product
or of the claims made of it by its manufacturer.
Thank you for considering Leukemia Research Reports for
your submission.
